1-7 of 7
John Lunec
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma

Inge M. Ambros, Bettina Brunner, Gerhard Aigner, Clare Bedwell, Klaus Beiske, Jean Bénard, Nick Bown, Valerie Combaret, Jerome Couturier, Raffaella Defferrari, Nicole Gross, Marta Jeison, John Lunec, Barbara Marques, Tommy Martinsson, Katia Mazzocco, Rosa Noguera, Gudrun Schleiermacher, Frank Speleman, Ray Stallings, Gian Paolo Tonini, Deborah A. Tweddle, Alexander Valent, Ales Vicha, Nadine Van Roy, Eva Villamon, Andrea Ziegler, Sandra Preuner, Mario Drobics, Ruth Ladenstein, Gabriele Amann, Robert J.L. Schuit, Ulrike Pötschger, Peter F. Ambros
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 792–804.
https://doi.org/10.1158/1078-0432.CCR-10-0830
Published: 15 February 2011
View article titled, A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma
Open the PDF for A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma in another window
Journal Articles

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

Jane Carr-Wilkinson, Kieran O'Toole, Katrina M. Wood, Christine C. Challen, Angela G. Baker, Julian R. Board, Laura Evans, Michael Cole, Nai-Kong V. Cheung, Joachim Boos, Gabriele Köhler, Ivo Leuschner, Andrew D.J. Pearson, John Lunec, Deborah A. Tweddle
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1108–1118.
https://doi.org/10.1158/1078-0432.CCR-09-1865
Published: 15 February 2010
View article titled, High Frequency of p53/MDM2/p14<sup>ARF</sup> Pathway Abnormalities in Relapsed Neuroblastoma
Open the PDF for High Frequency of p53/MDM2/p14<sup>ARF</sup> Pathway Abnormalities in Relapsed Neuroblastoma in another window
Journal Articles

Development of a Real-Time Polymerase Chain Reaction Assay for Prediction of the Uptake of Meta-[131I]iodobenzylguanidine by Neuroblastoma Tumors

Sean Carlin, Rob J. Mairs, Anthony G. McCluskey, Deborah A. Tweddle, Alan Sprigg, Christine Estlin, Julian Board, Rani E. George, Caroline Ellershaw, Andrew D. J. Pearson, John Lunec, Paolo G. Montaldo, Mirco Ponzoni, Berthe L. van Eck-Smit, Cees A. Hoefnagel, Marieke D. van den Brug, Godelieve A. M. Tytgat, Huib N. Caron
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3338–3344.
Published: 05 September 2003
View article titled, Development of a Real-Time Polymerase Chain Reaction Assay for Prediction of the Uptake of Meta-[<sup>131</sup>I]iodobenzylguanidine by Neuroblastoma Tumors
Open the PDF for Development of a Real-Time Polymerase Chain Reaction Assay for Prediction of the Uptake of Meta-[<sup>131</sup>I]iodobenzylguanidine by Neuroblastoma Tumors in another window
Journal Articles

Alteration in Urinary Matrix Metalloproteinase-9 to Tissue Inhibitor of Metalloproteinase-1 Ratio Predicts Recurrence in Nonmuscle-invasive Bladder Cancer

Garrett C. Durkan, Joyce E. Nutt, Colin Marsh, Paul H. Rajjayabun, Mary C. Robinson, David E. Neal, John Lunec, J. Kilian Mellon
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2576–2582.
Published: 01 July 2003
View article titled, Alteration in Urinary Matrix Metalloproteinase-9 to Tissue Inhibitor of Metalloproteinase-1 Ratio Predicts Recurrence in Nonmuscle-invasive Bladder Cancer
Open the PDF for Alteration in Urinary Matrix Metalloproteinase-9 to Tissue Inhibitor of Metalloproteinase-1 Ratio Predicts Recurrence in Nonmuscle-invasive Bladder Cancer in another window
Journal Articles

Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples from Patients with Transitional Cell Carcinoma of the Bladder

Garrett C. Durkan, Joyce E. Nutt, Paul H. Rajjayabun, David E. Neal, John Lunec, J. Kilian Mellon
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (11): 3450–3456.
Published: 01 November 2001
View article titled, Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples from Patients with Transitional Cell Carcinoma of the Bladder
Open the PDF for Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples from Patients with Transitional Cell Carcinoma of the Bladder in another window
Journal Articles

The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs

Xiaohong Lu, Julie Errington, Nicola J. Curtin, John Lunec, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 2114–2123.
Published: 01 July 2001
View article titled, The Impact of <em>p53</em> Status on Cellular Sensitivity to Antifolate Drugs
Open the PDF for The Impact of <em>p53</em> Status on Cellular Sensitivity to Antifolate Drugs in another window
Journal Articles

Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of de Novo Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines

Matthew J. Barnes, Edward J. Estlin, Gordon A. Taylor, G. Wynne Aherne, A. Hardcastle, J. J. McGuire, Joanne A. Calvete, John Lunec, Andrew D. J. Pearson, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2548–2558.
Published: 01 September 1999
View article titled, Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of <em>de Novo</em> Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines
Open the PDF for Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of <em>de Novo</em> Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines in another window